Company news

Aclarion, Inc. (NASDAQ:ACON) news

Aclarion, Inc. news releases on 6ix. Latest, Sep 29, 2026: Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites

Aclarion, Inc. (NASDAQ:ACON) news

Press releases & updates

Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites

Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology

Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026

Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical Practice

Aclarion Announces Texas Spine Care Center as New CLARITY Site

Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal

Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study

Aclarion, Inc. Comments on Echo Lake Capital’s Letter and Unsolicited Proposal

Echo Lake Capital Offers To Acquire Aclarion Inc.

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.

Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine

Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption

Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan

Aclarion Announces $2.5 Million Stock Repurchase Plan

Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain

Aclarion Receives Pinnacle Award for AI Innovation

Aclarion Announces Agreement with Weill Cornell Medicine

Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video

Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts

Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet

Aclarion CEO Brent Ness to Attend LSI USA 2026

Aclarion Publishes 2026 Shareholder Letter from the Chairman

Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation

Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028

Aclarion Provides 2025 Update and 2026 Corporate Outlook

Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data

Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)

Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst

Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference

Aclarion to Present at the LD Micro Main Event XIX

Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Aclarion Presents at LSI Europe ’25 Highlighting Nociscan Technology and Key Value Drivers

First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial

Aclarion Appoints Greg Gould as Chief Financial Officer

Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial

Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum

Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site

Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

Aclarion Announces Texas Back Institute as New CLARITY Trial Site